TP63 and ovarian carcinoma: Overexpressing of FZD7 activates the oncogenic factor tumor protein 63 (TP63), leading to increased levels of glutathione metabolic pathways, including GPX4, which protects cells against chemotherapy-induced oxidative stress and ferroptosis.208 FZD7 knockdown improves the sensitivity to platinum, reduces the formation of spheroids, and inhibits tumor growth.208 GPX4 inhibitors also induce ferroptosis and increase chemotherapy sensitivity in FZD7+ platinum-resistant ovarian cancer cells.